depends what you are measuring. Access to specific expensive remedies is a little more difficult. In Canada too. On the other hand, in the US you have people who have no access to care at all.
On 6/13/07, Sam <[EMAIL PROTECTED]> wrote: > I would call this piss poor. > > reposted form May 11 > > http://www.telegraph.co.uk/news/main.jhtml?xml=/news/2007/05/10/ncancer10.xml > > "To some extent this is determined by economic factors, but much of > the variation between countries remains unexplained. In the US we have > found that the survival of cancer patients is significantly related to > the introduction of new oncology drugs." > > The researchers, whose report is published in the journal Annals of > Oncology, found that Austria, France, Switzerland and the US were > leaders in using new cancer drugs. > > The greatest differences in the uptake of drugs were noted for the new > colorectal and lung cancer drugs. > > The proportion of colorectal cancer patients with access to the drug > Avastin was 10 times higher in the US than it was in Europe, with the > UK having a lower uptake than the European average. > > > On 6/13/07, Wayne Putterill <[EMAIL PROTECTED]> wrote: > > Point 2 - how about the National Health Service in the UK, seems to work > > pretty well? > > > > ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~| ColdFusion MX7 and Flex 2 Build sales & marketing dashboard RIAâs for your business. Upgrade now http://www.adobe.com/products/coldfusion/flex2?sdid=RVJT Archive: http://www.houseoffusion.com/groups/CF-Community/message.cfm/messageid:236556 Subscription: http://www.houseoffusion.com/groups/CF-Community/subscribe.cfm Unsubscribe: http://www.houseoffusion.com/cf_lists/unsubscribe.cfm?user=89.70.5
